Filing Flows › Inogen (INGN) › Q2 2026 › vs Q2 2025
Inogen (INGN) Q2 2026 vs Q2 2025 (year over year)
Inogen's revenue rose $2.8M (+3%) from $92.3M in Q2 2025 to $95.1M in Q2 2026.
Inogen, Q2 2026: revenue $95.1M (+3% year over year), operating margin -5.4%, net loss $3.9M, operating cash flow $2.9M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 2.4% | 4.0% | -1.6 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $95.1M | $92.3M | $2.8M | +3% |
| Other income, net | $1.1M | $1.8M | −$732K | -40% |
| Income tax benefit | $154K | $153K | $1K | +0.7% |
| Net loss | $3.9M | $4.2M | −$302K | -7% |
| Costs & expenses | $100M | $98.4M | $1.8M | +2% |
| Operating costs | $100M | $98.4M | $1.8M | +2% |
| Cost of revenue | $51.8M | $50.9M | $876K | +2% |
| Research & development | $5.9M | $5.2M | $662K | +13% |
| Sales & marketing | $24.8M | $25.4M | −$566K | -2% |
| General & admin | $17.7M | $16.9M | $802K | +5% |
| Operating cash sources | $6.8M | $8.5M | −$1.7M | -20% |
| Depreciation & amortization | $4.7M | $5.2M | −$519K | -10% |
| Share-based compensation | $1.8M | $2.3M | −$522K | -23% |
| Working capital & other | $328K | $993K | −$665K | -67% |
| Net loss absorbed | $3.9M | $4.2M | −$302K | -7% |
| Operating cash flow | $2.9M | $4.3M | −$1.4M | -32% |
| Free cash flow (OCF − capex) | $2.2M | $3.7M | −$1.4M | -39% |
| Capital expenditures | $711K | $684K | $27K | +4% |
Questions
How much did Inogen's revenue grow year over year in Q2 2026?
Inogen's revenue rose $2.8M (+3%) from $92.3M in Q2 2025 to $95.1M in Q2 2026.